Patents by Inventor John Edward Park

John Edward Park has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FAP-activated anti-tumor compounds
    Publication number: 20030232742
    Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug is chemically stable under physiological conditions and can be used for the manufacture of physically stable aqueous formulations. It has a cleavage site which is recognised by FAP&agr;, and the drug released by the enzymatic activity of FAP&agr; is cytotoxic or cytostatic under physiological conditions.
    Type: Application
    Filed: November 9, 2001
    Publication date: December 18, 2003
    Inventors: Stefan Peters, Dietmar Leipert, Christian Eickmeier, John Edward Park, Martin Lenter, Pilar Garin-Chesa, Juergen Mack
  • FAP-activated anti-tumor compounds
    Publication number: 20030211979
    Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug is chemically stable under physiological conditions and can be used for the manufacture of physically stable aqueous formulations. It has a cleavage site which is recognised by FAP&agr;, and the drug released by the enzymatic activity of FAP&agr; is cytotoxic or cytostatic under physiological conditions.
    Type: Application
    Filed: January 3, 2003
    Publication date: November 13, 2003
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Stefan Blech, Pilar Garin-Chesa, Martin Lenter, John Edward Park, Stefan Peters, Steffen Breitfelder
  • FAPalpha -specific antibody with improved producibility
    Publication number: 20030143229
    Abstract: Recombinant antibody proteins are provided that specifically bind fibroblast activation protein alpha (FAP&agr;) and comprise framework modifications resulting in the improved producibility in host cells. The invention also relates to the use of said antibodies for diagnostic and therapeutic purposes and methods of producing said antibodies.
    Type: Application
    Filed: June 3, 2002
    Publication date: July 31, 2003
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: John Edward Park, Pilar Garin-Chesa, Uwe Bamberger, Wolfgang J. Rettig, Olivier Leger, Jose William Saldanha
  • FAP-activated anti-tumor compounds
    Publication number: 20030055052
    Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug having a cleavage site which is recognised by FAP&agr;, and said drug being cytotoxic or cytostatic under physiological conditions.
    Type: Application
    Filed: November 9, 2001
    Publication date: March 20, 2003
    Inventors: Stefan Peters, Dietmar Leipert, John Edward Park, Martin Lenter, Pilar Garin-Chesa
  • FAP-activated anti-tumor compounds
    Publication number: 20020155565
    Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug having a cleavage site which is recognized by FAP&agr;, and said drug being cytotoxic or cytostatic under physiological conditions, wherein said prodrug comprises an oligomeric part comprising at least two amino carboxylic residues, and a cytotoxic or cytostatic part, wherein the C-terminal amino carboxylic residue of the oligomeric part is an acyclic amino acid, the nitrogen atom of the amino function thereof is attached to a substituent being different from a hydrogen atom, and the C-terminal carboxy function thereof is linked to the cytotoxic or cytostatic part by an amide bond.
    Type: Application
    Filed: November 9, 2001
    Publication date: October 24, 2002
    Inventors: Pilar Garin-Chesa, John Edward Park, Stefan Peters, Dietmar Leipert, Juergen Mack, Martin Lenter
  • FAP&agr;-specific antibody with improved producibility
    Patent number: 6455677
    Abstract: Recombinant antibody proteins are provided that specifically bind fibroblast activation protein alpha (FAP&agr;) and comprise framework modifications resulting in the improved producibility in host cells. The invention also relates to the use of said antibodies for diagnostic and therapeutic purposes and methods of producing said antibodies.
    Type: Grant
    Filed: April 29, 1999
    Date of Patent: September 24, 2002
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: John Edward Park, Pilar Garin-Chesa, Uwe Bamberger, Wolfgang J. Rettig, Olivier Lèger, Jose William Saldanha
  • Human FAP-alpha-specific antibodies
    Publication number: 20020099180
    Abstract: The invention relates to antibody proteins which specifically bind fibroblast activating protein alpha (FAP&agr;). The invention further relates to the use of said antibodies for diagnostic and therapeutic purposes as well as processes for preparing said antibodies.
    Type: Application
    Filed: March 19, 2001
    Publication date: July 25, 2002
    Inventors: Klaus Pfizenmaier, Dieter Moosmayer, Michael Mersmann, Alexej Schmidt, John-Edward Park, Pilar Garin-Chesa
  • FAPALPHA-SPECIFIC ANTIBODY WITH IMPROVED PRODUCIBILITY
    Publication number: 20020052480
    Abstract: Recombinant antibody proteins are provided that specifically bind fibroblast activation protein alpha (FAP&agr;) and comprise framework modifications resulting in the improved producibility in host cells. The invention also relates to the use of said antibodies for diagnostic and therapeutic purposes and methods of producing said antibodies.
    Type: Application
    Filed: April 29, 1999
    Publication date: May 2, 2002
    Inventors: JOHN EDWARD PARK, PILAR GARIN-CHESA, UWE BAMBERGER, WOLFGANG J. RETTIG, OLIVIER LEGER, JOSE WILLIAM SALDANHA